Tumor Protein p63-Regulated Gene 1 (TPRG1) as a Drug Target and Biomarker

Target Name: TPRG1

NCBI ID: G285386

TPRG1

Tumor Protein p63-Regulated Gene 1 (TPRG1) as a Drug Target and Biomarker

Introduction

Tumor protein p63-regulated gene 1 (TPRG1) is a tumor suppressor gene, which plays a crucial role in regulating cell growth and division. TPRG1 gene mutations can lead to tumorigenesis. Activation of the TPRG1 gene can lead to the occurrence of various tumors, including liver cancer, breast cancer, gastric cancer, etc. Silencing of TPRG1 gene can lead to tumor cell apoptosis. Therefore, the TPRG1 gene has become an important drug target and biomarker.

Function of TPRG1 gene

The TPRG1 gene is a transcription factor mainly expressed in tumor cells such as liver cells, oral epithelial cells, and colon cancer. The coding region of the TPRG1 gene contains a transcription factor binding domain, a DNA binding domain and a TAD (transcription factor binding domain) binding domain. The transcription factor binding domain of the TPRG1 gene is a transcription factor binding site that can bind to transcription factors, thereby promoting the transcription of the TPRG1 gene. The DNA-binding domain of the TPRG1 gene is a DNA-binding site that can bind to DNA to regulate the gene expression of the TPRG1 gene. The TAD binding domain of the TPRG1 gene is a transcription factor binding site that can bind to transcription factors, thereby promoting the transcription of the TPRG1 gene.

The tumorigenesis mechanism of TPRG1 gene

Mutations in the TPRG1 gene can lead to tumorigenesis. Mutations in the TPRG1 gene will lead to a reduction in its binding ability to transcription factors, resulting in a reduction in the gene expression of the TPRG1 gene. In addition, mutations in the TPRG1 gene can also lead to a reduction in its DNA binding ability, resulting in increased gene expression of the TPRG1 gene. Mutation of the TPRG1 gene will also lead to a reduction in its TAD binding ability, thereby reducing the binding ability of the transcription factor of the TPRG1 gene.

Drug targets of TPRG1 gene

Activation of the TPRG1 gene can lead to tumor cell apoptosis, so the TPRG1 gene can be used as a drug target. Currently, a variety of drugs that inhibit TPRG1 gene expression have entered clinical research, including anti-tumor drugs, anti-tumor vaccines, and gene therapy. These drugs can inhibit the transcription of the TPRG1 gene, thereby inhibiting the growth and division of tumor cells.

Biomarkers of TPRG1 gene

The expression level of TPRG1 gene can be used as a biomarker to detect the growth and division of tumor cells. The expression level of TPRG1 gene can be detected by gene expression technology, including PCR amplification, RNA sequencing and proteomics. The higher the expression level of the TPRG1 gene, the faster the tumor cells grow and divide. Therefore, the expression level of TPRG1 gene can be used as a biomarker to detect the growth and division of tumor cells.

Application prospects of TPRG1 gene

Activation of the TPRG1 gene can lead to tumor cell apoptosis, so the TPRG1 gene can be used as a drug target. Currently, a variety of drugs that inhibit TPRG1 gene expression have entered clinical research, including anti-tumor drugs, anti-tumor vaccines, and gene therapy. These drugs can inhibit the transcription of the TPRG1 gene, thereby inhibiting the growth and division of tumor cells. In addition, silencing of the TPRG1 gene can lead to tumor cell apoptosis, so the TPRG1 gene can be used as a biomarker to detect the growth and division of tumor cells.

Protein Name: Tumor Protein P63 Regulated 1

The "TPRG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPRG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets